2024年欧洲心脏病学会年会（ESC 2024）将于当地时间8月30日-9月2日在英国伦敦拉开帷幕，并同步举办线上会议。为期4天的会议涵盖心血管各领域前沿主题，并以多种形式呈现。其中，在心血管治疗药物主题中，公布了多项研究结果及进展，国际循环将持续跟踪报道，并邀请领域内专家深入解读，特邀您持续关注。本期整理了Cardiovascular Pharmacology部分日程，邀您一同查阅。
Cardiovascular Pharmacology
ESC 2024
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
抗血小板治疗：急性冠脉综合征和经皮冠状动脉介入治疗的新方法
北京时间：8月30日（周五）19:00
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
P2Y12抑制剂单药治疗急性冠脉综合征短DAPT后的系统评价和荟萃分析
北京时间：8月30日（周五）19:10
Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study
氯吡格雷与阿司匹林单药治疗经皮冠状动脉介入治疗后的二级预防——一项全国性人群研究
北京时间：8月30日（周五）19:20
Implementation of prasugrel and prognostic outcomes after percutaneous coronary intervention for myocardial infarction: a nationwide observational study
普拉格雷的实施和经皮冠状动脉介入治疗心肌梗死后的预后结果：一项全国性观察性研究
北京时间：8月30日（周五）19:30
Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry
不同 P2Y12 抑制剂对患有严重慢性肾脏病的急性冠脉综合征患者的影响：来自 CORALYS 登记处的见解
北京时间：8月30日（周五）19:40
Pretreatment with dual antiplatelet therapy in acute myocardial infarction
急性心肌梗死的双重抗血小板治疗预处理
北京时间：8月30日（周五）19:50
Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks
血流动力学不稳定患者经皮冠状动脉介入治疗期间使用与不使用坎格瑞洛：一项关于益处和风险的队列研究
Drug interactions， efficacy， and safety
药物的相互作用、疗效和安全性
北京时间：8月30日（周五）22:00-22:50
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
他汀类药物治疗中潜在药物相互作用导致的不良心血管结局：一项基于人群的研究
Drug-drug interactions of empagliflozin and dapagliflozin
恩格列净和达格列净的药物相互作用
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors， ARBs or statins - A nationwide cohort study
育龄妇女使用ACEI、ARBs 或他汀类药物的妊娠保护：一项全国性队列研究
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
选择最有效和最安全的P2Y12抑制剂用于大于70岁的急性冠脉综合征患者：网络荟萃分析
A prospective analysis of the efficacy and safety of ethacizine during premature atrial contractions and premature ventricular contractions
乙沙西嗪在房性早搏和室性早搏期间的疗效和安全性的前瞻性分析
Digoxin loading doses for atrial fibrillation in critically Ⅲ patients
心房颤动Ⅲ级危重患者的地高辛负荷剂量
Antithrombotic and anticoagulant therapy in special populations
特殊人群的抗血栓和抗凝治疗
北京时间：8月30日（周五）23:00-23:50
Direct oral anticoagulants exhibit lower risks of mortality and bleeding compared to vitamin-k antagonists in atrial fibrillation patients on chronic hemodialysis: a meta-analysis
与维生素K拮抗剂相比，直接口服抗凝剂在慢性血液透析心房颤动患者中表现出更低的死亡和出血风险：荟萃分析
Medication adherence and antithrombotic therapy outcomes: insights from a post-hoc analysis of the AFIRE trial
药物依从性和抗血栓治疗结果：来自AFIRE试验子分析的见解
Impact of differences in body mass index， body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe
接受依度沙班治疗的心房颤动患者体重指数、体表面积和瘦体重差异对临床结果的影响：来自 ETNA-AF-Europe的4年随访数据
Haemorrhagic risk in elderly patients with atrial fibrillation that develop low platelet count during direct oral anticoagulant treatment: insights from the ATHERO-AF study.
在直接口服抗凝治疗期间出现低血小板计数的老年心房颤动患者的出血风险：来自 ATHERO-AF研究的见解
Silent cerebral microvascular disease and longitudinal risk of cognitive decline in atrial fibrillation
无症状脑微血管疾病和心房颤动认知能力下降的纵向风险
The role of anticoagulation in atrial high-rate episodes: a meta-analysis
抗凝治疗在房性心动过速中的作用：荟萃分析
The effect of oral anticoagulants on the incidence of dementia in patients with atrial fibrillation: a systematic review and meta-analysis
口服抗凝剂对心房颤动患者痴呆发病率的影响：系统评价和荟萃分析
Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries
口服抗凝剂治疗的NVAF患者中性别和种族差异对结局的影响：对Medicare受益人的真实世界评估
Trimetazidine reduces stroke risk in ischemic atrial fibrillation: a territory-wide， propensity-matched study
曲美他嗪降低缺血性心房颤动的卒中风险：一项全区域、倾向性匹配研究
Novel and old treatments， evidence in large populations
基于大规模人群证据的新型与传统治疗方法
北京时间：8月31日（周六）22:00-22:45
Ezetimibe use and mortality after myocardial infarction: a nationwide cohort study
依折麦布的使用与心肌梗死后死亡率：一项全国性队列研究
Ezetimibe plus statin combination vs. double dose statin for patients with dyslipidemia and ASCVD risk: a systematic review and meta-analysis
依折麦布加他汀类药物联合治疗血脂异常和ASCVD风险患者的双剂量他汀类药物的系统评价和荟萃分析
Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service
在真实世界环境中使用英克司兰进行降脂治疗：来自国家医疗保健服务的初步数据
Moderate-intensity statin combined with ezetimibe versus high-intensity statin monotherapy for secondary cardiovascular risk reduction: a systematic review and meta-analysis
中等强度他汀类药物联合依折麦布与高强度他汀类药物单药治疗降低继发性心血管风险的系统评价和荟萃分析
Efficacy and safety of intravenous iron therapy in heart failure patients with iron deficiency: a systematic review and meta-analysis of randomized controlled trials
静脉铁剂治疗缺铁性心力衰竭患者的疗效和安全性：随机对照试验的系统评价和荟萃分析
Prognostic implications of guideline-directed medical therapy in functional mitral regurgitation: a meta-analysis
指南指导药物治疗对功能性二尖瓣反流的预后意义：荟萃分析
Temporal trends and regional differences of initial oral antiarrhythmic drug options in patients with new-onset atrial fibrillation: a report from the GLORIA-AF registry
新发心房颤动患者初始口服抗心律失常药物选择的时间趋势和区域差异：来自 GLORIA-AF登记处的报告
Sex-related outcomes in patients receiving shortened or longer dual antiplatelet treatment after percutaneous coronary intervention: a systematic review and meta-analysis.
经皮冠状动脉介入治疗后接受缩短或延长双重抗血小板治疗患者的性别相关结局：系统评价和荟萃分析
Torsemide versus furosemide in patients with heart failure: a systematic review and meta-analysis
托拉塞米与呋塞米在心力衰竭患者中的比较：系统评价和荟萃分析
Lipid-lowering therapy: statins and beyond
降脂疗法：他汀类药物及其他药物
北京时间：8月31日（周六）23:00-23:50
Plasma statin concentrations do not correlate with statin-induced myalgia
血浆他汀类药物浓度与他汀类药物引起的肌痛无相关性
The high-dose statin treatment reduces neutrophil extracellular traps formation in patients with coronary artery disease
大剂量他汀类药物治疗可减少冠状动脉疾病患者中性粒细胞胞外诱捕网的形成
Long-term administration of atorvastatin had no effect on the occurrence and progression of spontaneous hypertensive intracerebral hemorrhage in mice
长期给予阿托伐他汀对小鼠自发性高血压脑出血的发生和进展没有影响
Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry
英克司兰在实际临床实践中的疗效和安全性，来自CHOLINET登记处的结果
Sex dsparities in LDL-C and Non-HDLC response to PCSK9 Inhibitors
LDL-C和非HDLC对PCSK9抑制剂反应的性别差异
Impact of allogenic Fecal Microbiota Transplantation (FMT) on lipid parameters in patients with metabolic syndrome (MetS): a meta-analysis
同种异体粪便微生物群移植（FMT）对代谢综合征（MetS）患者脂质参数的影响：荟萃分析
Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome
联合降脂治疗在急性冠脉综合征患者事件发生1个月后达到低密度脂蛋白胆固醇目标的疗效
Cardiovascular related polypharmacy and its association with liver and kidney impairment amongst individuals on lipid-lowering therapy: a cross-sectional study using primary care data
心血管相关多药治疗及其与降脂治疗个体肝肾损伤的关联：一项使用初级保健数据的横断面研究
Real-world evidence on the cardiovascular effects of therapies for diabetes
关于糖尿病治疗对心血管影响的真实世界证据
北京时间：9月1日（周日）21:00-21:50
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
超重和肥胖患者接受减重试验的心血管代谢结局：一项网络荟萃分析
The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank
使用二甲双胍对2型糖尿病患者心房颤动风险的影响：来自英国生物样本库的数据
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation
达格列净对癌症患者心脏毒性发展的潜在保护作用的一年观察结果
All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries
使用丹麦注册数据比较使用SGLT-2抑制剂与DPP4抑制剂的2型糖尿病患者的全因死亡率
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report
恩格列净可改善2型糖尿病患者的动脉硬度：初步报告
Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service
通过提供增强的药师主导服务来识别和优化2型糖尿病患者的风险分层队列
Association of HbA1C with mortality and cardiovascular outcome in patients with type 2 diabetes using drugs with different hypoglycemic risk
不同降糖风险药物对2型糖尿病患者中HbA1c与死亡率及心血管结局的关联研究
Use of new antidiabetic drugs in patients with cardiovascular diseases - real life data
在心血管疾病患者中使用新的抗糖尿病药物：真实世界数据
The efficacy and safety of GLP-1 agonists to modify cardiovascular morbidity in patients with obesity without diabetes mellitus: a meta-analysis involving 32，884 patients
GLP-1激动剂改善无糖尿病肥胖患者心血管发病率的疗效和安全性：一项涉及 32，884名患者的荟萃分析
Novel drugs for cardiovascular diseases
治疗心血管疾病的新药
北京时间：9月1日（周日）21:30
Zibotentan in microvascular angina: a randomized， placebo-controlled， crossover trial
齐泊腾坦治疗微血管心绞痛中的应用：一项随机、安慰剂对照、交叉试验
北京时间：9月1日（周日）21:40
Inhibition of ceramide de novo synthesis mitigates atherosclerosis
抑制神经酰胺从头合成可减轻动脉粥样硬化
北京时间：9月1日（周日）21:50
Experimental evidence on colchicine's mode of action in human carotid artery plaques
秋水仙碱在颈动脉斑块中作用方式的实验证据
北京时间：9月1日（周日）22:00
The short-term prognosis of salvianolate use during hospitalization in patients with acute myocardial infarction
急性心肌梗死患者住院期间使用丹参多酚酸盐的短期预后
北京时间：9月1日（周日）22:10
Safety， tolerability， and basic pharmacokinetic parameters of AUX-001， a once-daily extended release nicorandil in healthy volunteers under fasting and fed conditions
AUX-001（一种每日一次缓释尼可地尔）在空腹和饱腹状态下健康志愿者中的安全性、耐受性和基本药代动力学参数
北京时间：9月1日（周日）22:20
SHR-1918， a monoclonal antibody against angiopoietin-like 3， in healthy subjects: a randomized， double-blind， placebo-controlled， phase 1 study
SHR-1918（一种抗血管生成素样蛋白3的单克隆抗体）在健康受试者中的应用：一项随机、双盲、安慰剂对照的I期研究
Diabetes， obesity， and the heart
糖尿病、肥胖症和心脏
北京时间：9月1日（周日）22:00-22:50
Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study
达格列净与恩格列净治疗2型糖尿病的主要不良心血管事件：一项全国性队列研究
GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis
GLP1-RA与DPP4抑制剂对心血管结局的影响：一项为期三年的真实世界分析
The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在心外膜脂肪组织调节中的作用：荟萃分析
Long-term prognostic impact of SGLT2 inhibitors in patients with type 2 diabetes mellitus and coronary ischemia
SGLT2抑制剂对2型糖尿病和冠状动脉缺血患者的长期预后影响
The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease
胰高血糖素样肽-1受体激动剂对2型糖尿病冠状动脉疾病患者心血管结局的影响
Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus
SGLT2抑制剂达格列净对长期1型糖尿病大鼠心肌蛋白谱的影响
Body mass index and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
THEMIS研究中糖尿病伴稳定性冠心病患者的体重指数与临床结局
Effect of sodium-glucose cotransporter-2 inhibitor (SGLT2-i) in patients with LVAD: a systematic review and meta-analysis
钠-葡萄糖协同转运蛋白-2 抑制剂（SGLT2-i）对LVAD患者的影响：系统评价和荟萃分析
Pharmacogenomics， cardio-omics， and cardiovascular drugs
药物基因组学、心脏组学和心血管药物
北京时间：9月1日（周日）23:00-23:50
Potential use of pharmacogenetics in cardiology: genome-wide association studies of amiodarone-induced thyroid disorders
药物遗传学在心脏病学中的潜在应用：胺碘酮诱导的甲状腺疾病的全基因组关联研究
Pharmacogenomics of CRP response to statins: a GIST consortium study
他汀类药物对CRP反应的药物基因组学：一项GIST联盟研究
Evaluating off-target drug effects seen in RCTs using proteomics and mendelian randomisation
利用蛋白质组学和孟德尔随机化评估随机对照试验中的药物脱靶效应
Evaluating CYP2D6 genotype-based impact on the clinical response to metoprolol
评估基于 CYP2D6 基因型对美托洛尔临床反应的影响
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
不同抗血小板策略对CYP2C19功能丧失等位基因携带者的影响比较：网络荟萃分析
Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients
基因型指导的P2Y12抑制剂降级策略在急性冠脉综合征患者中的实施
Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists
氯吡格雷药物基因组学指南在心脏病专家中的知名度和接受度有限
Integrated multi-omics predictive analysis of atherosclerosis: a sub-study from the Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) trial
动脉粥样硬化的综合多组学预测分析：糖尿病动脉粥样硬化（MAGMA）试验中盐皮质激素受体拮抗作用的子研究
iRight4Me: individualisation of P2Y12 inihibitors in the realworld practice - an interim report
iRight4Me：真实世界中P2Y12抑制剂的个体化应用——中期报告
Novel anticoagulants and indications
新型抗凝剂和适应证
北京时间：9月2日（周一）20:00-20:50
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials
左心室血栓患者的直接口服抗凝剂或华法林：随机临床试验的荟萃分析
Direct Oral Anticoagulants versus Vitamin K Antagonists for the management of left ventricular thrombus after myocardial infarction: A meta-analysis
直接口服抗凝剂与维生素K拮抗剂治疗心肌梗死后左心室血栓的荟萃分析
Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: a post-hoc sub-study of ETNA-AF-Europe
依度沙班用于伴有和不伴有动脉粥样硬化疾病的房颤患者的卒中预防：ETNA-AF-Europe研究的亚组研究
Unfractionated heparin or low molecular weight heparin in patients with acute pulmonary embolism: a meta-analysis of randomized controlled trials
急性肺栓塞患者的普通肝素或低分子肝素：随机对照试验的荟萃分析
Direct oral anticoagulants in embolic stroke of undetermined source: an updated meta-analysis
直接口服抗凝剂治疗未明原因的栓塞性卒中：更新的荟萃分析
Antithrombotic strategies after cryptogenic stroke: a systematic review， pairwise， and network meta-analysis of randomized controlled trials
隐源性卒中后的抗血栓策略：随机对照试验的系统评价和网络荟萃分析
Characterisation of the pharmacokinetic and pharmacodynamic relationship of milvexian in total knee replacement patients
milvexian在全膝关节置换患者中的药代动力学和药效学关系的表征
Prevention of mechanical valve thrombosis with a combination of the factor Xa inhibitor edoxaban plus aspirin in swine: intermediate results from the EdoValves project
Xa因子抑制剂依度沙班联合阿司匹林预防机械瓣膜血栓形成：EdoValves项目的中期结果
Cardiovascular pharmacotherapy: new insights
心血管药物治疗：新见解
北京时间：9月2日（周一）22:00-22:50
The effect of Lipoprotein[a] on vascular dementia and cardiovascular diseases: a drug target Mendelian randomization
脂蛋白[a]对血管性痴呆和心血管疾病的影响：一项药物靶点孟德尔随机化研究
Glutathione s-transferase pi is a marker of loop diuretic resistance in patients with congestive heart failure exacerbation
谷胱甘肽s-转移酶“pi”是充血性心力衰竭加重患者袢利尿剂耐药的标志物
Shortened versus standard duration of dual antiplatelet treatment after percutaneous coronary intervention in patients with and without chronic kidney disease: a systematic review and meta-analysis
经皮冠状动脉介入治疗术后缩短与标准时长双联抗血小板治疗对伴有和不伴有慢性肾病患者的影响：一项系统综述与荟萃分析
The impact of body mass on cardiovascular outcomes in patients with acute coronary syndrome
体重对急性冠脉综合征患者心血管结局的影响
Personalising antithrombotic strategies in acute and chronic coronary syndromes: when and how to escalate and de-escalate
急性和慢性冠脉综合征的个性化抗血栓形成策略：何时以及如何升级和降级
北京时间：9月2日（周一）22:15
Reducing intensity of dual antiplatelet therapy in acute coronary syndromes: what is the optimal timing?
降低急性冠脉综合征中双重抗血小板治疗的强度：最佳时机？
北京时间：9月2日（周一）22:35
Shortening dual antiplatelet therapy duration in acute coronary syndromes: should we drop aspirin or the P2Y12 inhibitor?
缩短急性冠脉综合征的双重抗血小板治疗持续时间：应该放弃阿司匹林还是P2Y12抑制剂？
北京时间：9月2日（周一）22:55
When and how to escalate antithrombotic therapy beyond aspirin in chronic coronary syndromes
在慢性冠脉综合征中，何时以及如何将抗血栓治疗升级为阿司匹林
京公网安备 11010502033353号